Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Buy” by Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned an average rating of “Buy” from the eight analysts that are covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $19.43.

A number of equities analysts have commented on the company. Jefferies Financial Group increased their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. HC Wainwright increased their target price on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. BMO Capital Markets increased their target price on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. upped their price target on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP grew its position in Replimune Group by 156.6% in the fourth quarter. Woodline Partners LP now owns 854,309 shares of the company’s stock worth $10,346,000 after acquiring an additional 521,366 shares during the period. Velan Capital Investment Management LP purchased a new position in Replimune Group in the fourth quarter worth approximately $2,196,000. Soleus Capital Management L.P. purchased a new position in Replimune Group in the fourth quarter worth approximately $3,179,000. Two Sigma Investments LP grew its position in Replimune Group by 18.6% in the fourth quarter. Two Sigma Investments LP now owns 212,586 shares of the company’s stock worth $2,574,000 after acquiring an additional 33,346 shares during the period. Finally, Tang Capital Management LLC grew its position in Replimune Group by 125.0% in the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock worth $32,697,000 after acquiring an additional 1,500,000 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Stock Performance

NASDAQ REPL opened at $11.65 on Monday. The stock has a market capitalization of $897.22 million, a price-to-earnings ratio of -3.79 and a beta of 1.30. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock has a 50-day moving average of $12.66 and a 200 day moving average of $12.13.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Sell-side analysts anticipate that Replimune Group will post -2.97 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.